BioEclipse Therapeutics™ | NEXT GENERATION OF …
With our unique low-cost allogeneic (CRX200, IND ready) and autologous (CRX100, Phase 1b) therapies, we have demonstrated the power of an engineered immune attack against the …
BioEclipse Receives FDA Clearance of Investigational New Drug ...
Apr 28, 2020 · BioEclipse Therapeutics™ is preparing to initiate Phase I clinical trials with, CRX-100, a patented, first in class, intravenously delivered, targeted immunotherapy against solid …
BioEclipse Therapeutics™ | BioEclipse Initiates Enrollment in Phase …
Dec 21, 2020 · Developed with technology exclusively licensed from Stanford University, CRX100 combines activated immune cells, known as cytokine-induced killer (CIK) cells, with a tumor …
CRX-100 by BioEclipse Therapeutics for Non-Small Cell Lung …
The company’s lead product candidate, CRX-100, a combined immunotherapy designed to target and kill cancer cells throughout the body while triggering an immune response that may …
Ozmosi | CRX-100 Drug Profile
CRX-100 is being developed by BioEclipse Therapeutis for the treatment of patients with advanced solid tumors. (Sourced from: …
CRX-100 - Drug Targets, Indications, Patents - Synapse
BioEclipse Therapeutics™ initiated a Phase 1 clinical trial with CRX100, a patented, first-in-class, intravenously delivered, targeted immunotherapy against solid tumors. CRX100 is being …
PHASE 1, OPEN LABEL, DOSE-ESCALATION STUDY OF CRX100 IN …
The virus is designed to specifically attack and kill tumors and stimulate the patient’s immune system to attack the tumor cells. The goal is to eradicate the primary tumor and prevent …
BioEclipse Receives FDA Clearance of Investigational New Drug ...
Apr 28, 2020 · BioEclipse Therapeutics™ is preparing to initiate Phase I clinical trials with, CRX-100, a patented, first in class, intravenously delivered, targeted immunotherapy against solid …
Study of CRX100 Makes Progress in Patients With Refractory Solid Tumors
Mar 5, 2021 · Investigators anticipate the CIK cells will protect the oncolytic virus and deliver it to the cancer cells in the body to attack primary tumors and metastatic disease. Preclinical …
CRX-100 by BioEclipse Therapeutics for Melanoma: Likelihood of …
The company’s lead product candidate, CRX-100, a combined immunotherapy designed to target and kill cancer cells throughout the body while triggering an immune response that may …
- Some results have been removed